Neuroendocrine neoplasms of the ovary: a review of 63 cases
- 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- 2Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- 0Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
|
April 14, 2025
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ovarian neuroendocrine neoplasms, particularly neuroendocrine carcinomas, show higher recurrence and worse survival than carcinoid tumors. Misdiagnosis is common, impacting treatment and outcomes for these rare ovarian tumors.
Area Of Science
- Gynecologic Oncology
- Endocrine Pathology
- Cancer Epidemiology
Background
- Ovarian neuroendocrine neoplasms are rare tumors with poorly defined clinicopathological characteristics and survival outcomes.
- Distinguishing between carcinoid tumors and neuroendocrine carcinomas is crucial for prognostication and treatment planning.
Purpose Of The Study
- To delineate the clinicopathological features and survival patterns of ovarian neuroendocrine neoplasms.
- To compare outcomes between carcinoid tumors and neuroendocrine carcinomas within a curated registry.
Main Methods
- Retrospective analysis of 63 patients with confirmed ovarian neuroendocrine neoplasms from a registry.
- Exclusion of small cell carcinomas and tumors with neuroendocrine features only.
- Categorization into carcinoid tumors and neuroendocrine carcinomas for comparative analysis of progression-free and overall survival using Kaplan-Meier and multivariable models.
Main Results
- Neuroendocrine carcinomas (79%) were more common than carcinoid tumors (21%).
- Neuroendocrine carcinomas had significantly worse 5-year overall survival (24%) and median survival (1.6 years) compared to carcinoid tumors (80% survival, 4.8 years median).
- High rates of misdiagnosis (46% in carcinomas) and recurrence (60% in carcinomas) were observed; advanced stage and pure histology predicted worse outcomes.
Conclusions
- Ovarian neuroendocrine carcinomas portend a poorer prognosis than carcinoid tumors, characterized by higher recurrence and mortality.
- Initial misdiagnosis is a significant issue in both subtypes, potentially delaying appropriate management.
- Admixed histology in neuroendocrine neoplasms is linked to increased progression risk.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.